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Abstract
Background: Bleeding negatively impacts quality of life in patients with unresectable advanced gastric cancer
and has the potential to be lethal. When blood transfusion and endoscopic hemostasis are unsuccessful to stop
bleeding, radiation to stomach is selected in patients with unsuitable condition for surgery. We performed a
retrospective cohort study to clarify the utility of radiotherapy in treating gastric bleeding, particularly for patients
with limited life expectancy.
Methods: We evaluated the efficacy and safety of palliative radiotherapy in patients with advanced gastric cancer
between January 2007 and December 2012 in Aichi Cancer Center Hospital. All patients had gastric bleeding
requiring blood transfusion. We defined hemostasis as an increase in hemoglobin level to more than 7.0 g/dL
together with the cessation of melena or hematemesis for at least 1 week.
Results: During the study period, 313 advanced gastric cancer patients treated in our institution. Of these 17
patients received gastric radiotherapy to stop bleeding. Two patients were excluded from analysis due to
combined treatment of intravascular embolization. Eleven out of 15 patients (73 %) had undergone two or
more previous chemotherapy regimens. Ten patients (67 %) had an Eastern Cooperative Oncology Group
performance status of 3 and 14 patients (93 %) were in palliative prognostic index group B or C. The median
total planned radiation dose was 30 Gy in 10 fractions. At a median interval of 2 days after initiation of radiotherapy,
11 patients (73 %) achieved hemostasis; rebleeding was observed in four patients (36 %). The median hemoglobin level
before radiotherapy was significantly increased from 6.0 to 9.0 g/dL (p < 0.0001). The median volume of red blood cell
transfusion was significantly decreased from 1120 to 280 mL (p = 0.007). The median rebleeding-free survival interval
was 27 days, with a median overall survival of 63 days. The cause of death was bleeding in 1 patient (7 %) and cancer
progression without bleeding in 12 patients (80 %). There were no severe adverse events attributable to radiotherapy.
Conclusions: Palliative radiotherapy for gastric bleeding achieves hemostasis within a short time frame. This appears to
be a useful treatment option, especially for patients with end-stage, unresectable advanced gastric cancer.
Keywords: Gastric cancer, Palliative care, Radiotherapy, Hemostasis, Bleeding
* Correspondence: hirochi1981@gmail.com
1Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1
Kanoko-den Chikusa-ku, Nagoya City, Aichi, Japan
3Department of Medical Oncology, Japanese Red Cross Nagoya Daiichi
Hospital, 3-35 Michishita-Cho, Nakamura-ku, Nagoya City, Aichi, Japan
Full list of author information is available at the end of the article
© 2015 Kondoh et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kondoh et al. BMC Palliative Care  (2015) 14:37 
DOI 10.1186/s12904-015-0034-y
Background
Adenocarcinoma of the stomach is a significant malady,
with a worldwide incidence of more than 900 000, causing
700 000 deaths in 2012 [1]. Patients with early gastric
cancer are commonly treated surgically and with advanced
locoregional disease are treated with multimodal approach
such as surgery followed by chemotherapy or chemoradio-
therapy [2–4] or perioperative chemotherapy or chemora-
diotherapy [5, 6]. For patients with advanced gastric
cancer (AGC), quality of life is negatively impacted when
the tumor causes obstruction and symptoms such as pain
or bleeding. Hemoglobin level of less than 6.5 g/dL is
categorized as life-threatning, blood transfusion is the only
intervention option for patients who require immediate
correction of anemia. According to the guidelines pub-
lished by the American Association of Blood Banks,
transfusion is recommended for hospitalized patients
without cardiovascular disease targeting the threshold
of hemoglobin level of 7 to 8 g/dL and depending on
their symptoms. [7] Radiotherapy (RT) is sometimes
used to treat severe anemia due to gastric bleeding in
patients with AGC who are not able to undergo sur-
gery, endoscopy, or intravascular embolization. The
efficacy of RT for bleeding has been evaluated in
patients with non-small-cell lung cancer, cervical can-
cer, and bladder cancer [8–11]. In patients with AGC,
between 54 and 80 % are able to achieve hemostasis
with RT [12–17]. In patients who complete a dose of
30 Gy or more, 91 % are hemostatic within 1 month
[16]. The survival time of patients with AGC who fail
standard chemotherapy is reportedly 3.8–4.3 months
[18–20]. In the present study, we attempted to refine
these measurements, focusing on the interval to achieve
hemostasis after initiating RT and the eventual cause of
death in patients with AGC. These parameters may be
more important to patients who are seeking palliative
rather than curative treatment.
Methods
Patients
For this retrospective cohort study, we reviewed the re-
cords of patients with unresectable AGC who received
palliative RT to control gastric bleeding. All patients
were treated at Aichi Cancer Center Hospital between
January 2007 and December 2012. The principal inclu-
sion criteria were: histologically proven inoperable
adenocarcinoma in the stomach or in the esophagogas-
tric junction, endoscopically confirmed gastric bleeding,
and at least one blood transfusion administered to
improve anemia before RT.
A total of 313 patients with AGC were treated at our
institution during the study period. Of these, 17 patients
had received gastric RT for hemostasis. Two patients
with hemorrhagic shock were excluded from analysis
due to a history of interventional radiology (IVR) proce-
dures administered within 7 days of beginning RT. All
patients gave written informed consent for treatment.
The review board of Aichi Cancer Center approved this
study and deemed informed consent unnecessary due to
its retrospective nature.
Radiotherapy
RT planning was performed using 3-dimensional radiation
planning system with 5 or 10-mm slice thickness of
computed tomography (CT) images. The clinical target
volume (CTV) was defined as primary lesion, with ad-
equate margins, based on the findings of both endoscopic
examination and CT images. Regional lymph nodes were
not included in the CTV. The planning treatment volume
(PTV) is created from CTV adding margin for clinical
treatment set-up. All patients were treated using external
10-MV photon beams from a linear accelerator. Typically,
a total dose of 30Gy in 10 fractions was delivered to the
PTV using the antero-posterior parallel opposed portals.
Evaluation of treatment and statistical analysis
The Eastern Cooperative Oncology Group performance
status (PS) and the Palliative Prognostic Index (PPI)
were used to evaluate patients [21, 22]. PPI is calculated
for each case based on palliative performance scale, the
amount of oral intake, and the presence of edema, dys-
pnea at rest, and delirium. Patients are divided into
groups according to projected survival time: group A, 4
to 5 months; group B, 3 months; and group C, less than
3 weeks [22].
Patients’ records were reviewed from the time point
30 days before initiating RT until their death. The day of
hemostasis was defined without endoscopic evidence as
the first day after starting RT that satisfied all of the fol-
lowing criteria for at least 7 consecutive days: an increase
in hemoglobin to greater than 7.0 g/dL, no evidence of
melena or hematemesis, and no indication for blood trans-
fusion. Patients who required other hemostatic procedures
such as IVR techniques or endoscopic procedures were
categorized as failing RT. Patients given blood transfusions
after achieving hemostasis were categorized as rebleeding.
Hematologic studies were conducted at least once
weekly. The change in hemoglobin level was determined
by evaluating the lowest point in the 30 days before
starting irradiation and the level 30 days after starting
RT; t-testing was used to compare these values. Toxicity
was evaluated within 30 days of initiating RT using the
National Cancer Institute Common Toxicity Criteria,
version 4.0.
Biologically effective dose (BED) is an approximate
quantity to compare the different fractionation regimens.
Using alpha/beta ratio of 10 for adenocarcinomas, BED
was calculated for each cases.
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Rebleeding-free survival (RFS) was measured from the
first day of RT until either rebleeding occurred or death
from any cause took place. Rebleeding was set at day1 of
RT for patients who never achieved hemostasis. Overall
survival (OS) was measured from the first day of RT
until death occurred. The median RFS and OS were de-
termined using the Kaplan-Meier method. Statistical
analysis was performed using JMP software, version
10.0.2 (Statistical Analysis Software, Inc., Cary, NC).




Patient characteristics are listed in Table 1. The median
follow-up time was 35.4 months (range, 0.9–82.0 months).
The median patient age was 61 years. Male patients pre-
dominated, and 67 % of all patients had a poor PS. A total
of eight patients (53 %) were in PPI group B, and six
patients (40 %) were in group C. The dominant histology
was poorly differentiated adenocarcinoma in seven
patients (47 %), and the tumor was located in the gastric
body in 11 patients (73 %). All patients had metastatic dis-
ease, and 10 (67 %) had organ metastases. Eleven patients
(73 %) had received two or more chemotherapy regimens
prior to beginning RT (median, 3 regimens).
Concurrent chemotherapy was administered in five
patients (33 %). The regimens were as follows: weekly
paclitaxel, weekly paclitaxel and trasutuzumab, metho-
trexate and 5-fluorouracil (5-FU), low-dose cisplatin and
5-FU, and FOLFOX (oxaliplatin, folinic acid and 5-FU).
Compared with the concurrent chemoRT group, the RT
alone group was older in median age. PPI group C and
peritoneal metastasis were less in RT alone group. The
other background factors were balanced between the
two groups. Chemotherapy regimens after completion of
RT were as follows: weekly paclitaxel in two patients,
methotrexate and 5-FU in one patient, trastuzumab and
lapatinib in one patient, and docetaxel in one patient.
Subsequent chemotherapy was administrated to two
patients (20 %) in RT alone group and to three patients
(60 %) in chemoRT group.
Treatment results
Twelve patients (80 %) received the dose-fraction regimen
of 30 Gy in 10 fractions corresponding to BED 39 Gy10.
The others were planned as 40Gy in 20 fractions, 36Gy in
18 fractions, and 30Gy in 12 fractions for one patient
respectively; these doses were completed in all but a single
patient (93 %) (Table 1). One patient with brain metasta-
ses discontinued RT after achieving hemostasis because of
restlessness during irradiation. All patients were treated
with supportive medications such as proton pump inhibi-
tors, tranexam acid and local thrombin.
Table 1 Patient characteristics








Median (range) 62 (57–87) 53 (42–71) 61 (42–87)
Sex
Male 70 (7) 80 (4) 73 (11)
ECOG performance status
1 0 20 (1) 1 (7)
2 30 (3) 20 (1) 4 (26)
3 70 (7) 60 (3) 10 (67)
Palliative prognostic index group [22]
A 0 20 (1) 7 (1)
B 70 (7) 20 (1) 53 (8)
C 30 (3) 60 (3) 40 (6)
Histological type
Well differentiated 10 (1) 20 (1) 13 (2)
Moderately
differentiated
50 (5) 20 (1) 40 (6)
Poorly
differentiated




20 (2) 40 (2) 27 (4)
Gastric corpus 80 (8) 60 (3) 73 (11)
Metastatic sitea
Lymph nodes 60 (6) 80 (4) 67 (10)
Liver 60 (6) 60 (3) 60 (9)
Peritoneum 30 (3) 60 (3) 40 (6)
Prior chemotherapeutic regimen
0 10 (1) 0 7 (1)
1 20 (2) 20 (1) 20 (3)
2 10 (1) 20 (1) 13 (2)
3 or more 60 (6) 60 (3) 60 (9)
Subsequent chemotherapyc
Yes 20 (2) 60 (3) 33 (5)
Radiotherapy dose (Gy)
30 80 (8) 80 (4) 80 (12)
>30 10 (1) 20 (1) 13 (2)
<30 10 (1) 0 7 (1)
Biologically effective dose (Gy10)
Median (range) 39 (23.4–43.2) 39 (39–48) 39 (23–48)
ECOG Eastern Cooperative Oncology Group
aOverlapped data
bPaclitaxel in 1; paclitaxel and trastuzumab in 1; methotrexate + 5-fluorouracil
(5-FU) in 1; oxaliplatin + folinic acid + 5-FU in 1; low dose cisplatin + 5-FU in 1
cPaclitaxel in 2; methotrexate + 5-FU in 1; docetaxel in 1; trastuzumab +
lapatinib in 1
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Eleven patients (73 %) achieved hemostasis. The median
time to hemostasis was 2 days (range, 1–9 days). The me-
dian hemostatic radiation dose was 6 Gy (range, 3–21 Gy).
In the four patients categorized as no hemostasis, no one
started RT with thrombocytopenia. Three patients re-
ceived RT alone and one patient received chemoRT. One
patient was rescued by arterial embolization technique
and stopped bleeding. None was performed endoscopic
procedures. The median hemoglobin level before RT was
6.0 g/dL; after 30 days, the median was 9.0 g/dL, a signifi-
cant increase (p < 0.001). The median platelet count was
291,000/mm3 (range, 6.0–53.3) on the day of starting RT.
The median red blood cell transfusion volume per month
significantly decreased, from 1120 mL pre-RT to 280 mL
after starting RT (p = 0.007) (Fig. 1). In the 11 patients
who achieved hemostasis, 4 experienced rebleeding
(36 %). At the time of rebleeding, the platelet count less
than 50,000/mm3 was observed in one patient with
disseminated intravascular coagulopathy due to bone
marrow metastasis. The median RFS was 27 days (95 %
confidential interval [CI], 1–94 days) (Fig. 2).
The cause of death was gastric bleeding in one patient
(7 %) and cancer progression in 12 patients (80 %). Two
patients (13 %) were still alive at the end of the study
period. The median OS was 63 days (95 % CI, 20–141
days) (Fig. 2).
In the five patients of chemoRT goup, four patients
stopped bleeding. Of them, two patients showed rebleed-
ing 27 and 147 days later respectively. The median OS
was 63 days (95%CI, 39–259 days).
Toxicity
Grade 1 nausea and pleural effusion were documented in
two patients. Fatigue, vomiting, and diarrhea were noted
in one patient each. One patient required treatment for
grade 2 hypertension after achieving hemostasis. As a
result of concurrent or subsequent chemotherapy, Grade
3/4 neutropenia was documented in 3 patients. Grade 4
thrombocytopenia and creatinine elevation developed in
one patient each, findings we attributed to disease pro-
gression (Table 2).
Discussion
Gastric cancer is not adequately sensitive to RT alone;
thus, multimodal therapeutic approaches with surgery
and chemotherapy have been developed [2–6, 23]. Hen-
ning et al. showed an advantage in locoregional control
in patients undergoing chemoradiation who received a
dose of greater than 54 Gy, but no OS benefit was seen
[24]. However, from the palliative point of view, Asakura
et al. reported that a radiation dose of 30 Gy in ten frac-
tures is adequate to control bleeding from gastric cancer
[15]. The hemostatic rate observed in the present study
is almost the same as Asakura et al’s and supports their
results.
The mechanism of hemostasis induced by irradiation
is not clearly identified. The irradiation procedure is
widely thought to aggregate platelets or to damage the
vascular endothelial cells. Radiation has also been shown
to induce embolism of vessels, both in vitro and in vivo
[25–27]. In the preclinical experimental models of rats
and mice, platelet aggregation is observed 3 min after ir-
radiation [28], with tissue factor (the primary initiator of
blood coagulation, expressed on peripheral mononuclear
cells) appearing after 1 day. Procoagulant activity is seen
for duration of 7 days [29]. These mechanisms may sup-
port the early hemostatic response to RT observed in
our patients.
OS and RFS are strongly associated with individual pa-
tient characteristics. Previous reports of palliative RT
a) b)
Fig. 1 a Comparison of hemoglobin levels prior to and 30 days after initiation of gastric radiation therapy (RT). The horizontal bars represent the
mean (long bar) and the range (short bars). b Comparison of the amount of transfused red blood cells 30 days before and 30 days after starting
gastric RT. The horizontal bars represent the mean (long bar) and the range (short bars)
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performed for gastric bleeding had study populations of
30–40 % chemo-naïve patients; 60–80 % had a good PS
(PS1/2). Our study population was 7 % chemo- naïve,
and 33 % had a good PS; hence, the prognosis of our
patients is the poorest reported thus far. Fourteen of our
patients (93 %) were categorized as PPI group B or C, a
finding that confers a prognosis of less than 3 months
survival but also indicates potential benefit from the use
of RT. In patients with such a limited life expectancy, it is
important to use minimally invasive treatment methods
whenever possible. Hypofractionated RT was previously
investigated, in a randomized, controlled trial, for the
management of patients with bladder cancer who are un-
suitable for curative treatment and who have an estimated
3-month survival prognosis [11]. A dose of 21 Gy in 3
fractions, given on alternate weekdays over 1 week, and a
dose of 35 Gy in 10 fractions, given over 2 weeks, pro-
duced improvement in symptoms in 64 and 71 % of pa-
tients, respectively, with no evidence of a difference in
efficacy or toxicity between the dosage groups. Hypofrac-
tionated RT may induce more late toxicity in patients
with other types of cancer [30], so it is recommended
only for patients with a limited life expectancy. In the
setting of AGC refractory to standard chemotherapy,
hypofractionated RT might be an option for patients in
PPI group B or C.
Previous studies have not provided information about the
cause of death in their patients. Although our results may
be fairly premature, with two patients still living, 80 % of
our patients died from disease progression, exhibiting organ
failure or physical debilitation, not bleeding from stomach.
One of the major limitations of the present study is
the method of patient selection. We excluded two
patients from analysis because they had previously
undergone intravascular catheter embolization. One of
these patients achieved hemostasis with RT alone, but
the other patient never stopped bleeding and went on
to die of hemorrhage. One of the study patients had
continuing hemorrhage after starting RT alone and
underwent IVR rescue treatment for a pseudoaneur-
ysm, detected along a branch of the left gastric artery.
The condition common to these 3 patients is hemorrhagic
shock, which may be an indicator of unsuitability for RT.
Other limitations of this study are the small sample size
and the retrospective, single-institution study design.
Conclusions
In conclusion, our results, although limited, suggest that
palliative RT may be a useful treatment option to control
gastric bleeding in patients with unresectable AGC.
Patients who respond to treatment typically achieve
hemostasis within 2 days, and the benefits persist for
longer than 1 month. These patients may avoid death
from hemorrhage. Additional investigation is necessary
in order to clarify the ideal RT dose and to select the
most appropriate candidates for treatment.
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Fig. 2 Rebleeding-free survival (RFS) and overall survival (OS) after
gastric radiation therapy
Table 2 Treatment toxicity
Toxicity Grade
1 2 3 4
Nausea 2 0 0 0
Vomiting 1 0 0 0
Diarrhea 1 0 0 0
Fatigue 1 0 0 0
Pleural effusion 2 0 0 0
Hypertension 0 1 0 0
Creatinine increased 1 0 0 1
Bilirubin increased 2 1 0 0
Neutropenia 3 0 1 2
Thrombocytopenia 2 1 0 1
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